Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Novo Nordisk shares have dropped ~50% since June ... Despite strong market share and promising early results for Amycretin, competition from Eli Lilly and regulatory risks pose significant challenges.

Novo Nordisk's sales have been growing fast thanks ... Last year, the Danish company delivered promising early-stage results for amycretin, another GLP-1 option. Amycretin is a dual agonist ...